NEW YORK (GenomeWeb News) – A Medicare contractor has issued a final coverage determination confirming coverage for one of Rosetta Genomics' microRNA-based cancer diagnostics, but denying Medicare coverage for two of the firm's other tests, Rosetta announced today.
NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has signed a credentialing agreement with Three Rivers Provider Network, which will offer the firm's Cancer Origin Test to members of the preferred provider organization.
Rosetta Genomics released an abstract for this years' annual meeting of the American Society of Clinical Oncology reiterating the concordance and sensitivity of its diagnostic test for cancers of unknown primary origin, and showing that the test frequently influences clinical dec
In a prospective study published this month, patients with cancer of unknown primary who were tested using BioTheranostics' CancerType ID assay, and who then received chemotherapy specific to their predicted tumor of origin, survived longer on average than expected for standard C
NEW YORK (GenomeWeb News) – Rosetta Genomics today said that Novitas, a designated Medicare contractor, has informed the firm that it plans to cover its miRview mets2 assay for all Medicare beneficiaries.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has granted the firm approval to begin processing patient samples from the state for its miRview mets^2 test.